High affinity inhibitors of PACE4 with therapeutic implications for prostate cancer

PACE4 的高亲和力抑制剂对前列腺癌的治疗意义

• 批准号: 401636
• 负责人: Day Robert
• 金额: $ 50.71万
• 依托单位: Universit de Sherbrooke
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-03-01 至 2024-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=401636&lang=en
• 关键词: C23; Cancer Animal Models; Drug Delivery; Enzyme Inhibitor; Imaging; Medicinal Chemistry; Pace4; Prodrugs; Structure Activity; Theranostics

Prostate cancer is the most important cancer in men. Recurrence is a major problem that kills over 4000 Canadian men per year. While anti-androgen therapies extend life, prostate cancer cells adapt and become resistant. Novel, non-androgen targeted therap

前列腺癌是男性最重要的癌症。复发是一个主要问题，每年造成4000多名加拿大男子死亡。虽然抗雄激素治疗延长了生命，但前列腺癌细胞适应并产生耐药性。新型非雄激素靶向治疗